A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.

被引：0
作者：
Shaikh, Saba
Zang, Yan
Hanmer, Janel
Wang, Hong
Lin, Yan
Davar, Diwakar
Zarour, Hassane M.
Kirkwood, John M.
Najjar, Yana G.
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21506
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.
    Larkin, James M. G.
    Yan, Yibing
    McArthur, Grant A.
    Ascierto, Paolo Antonio
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev V.
    Stroyakovskiy, Daniil
    Thomas, Luc
    De La Cruz-Merino, Luis
    Atkinson, Victoria
    Dutriaux, Caroline
    Garbe, Claus
    Wongchenko, Matthew
    Rooney, Isabelle Anne
    Chang, Ilsung
    Hack, Stephen Paul
    Dreno, Brigitte
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
    Svane, Inge Marie
    Nair, Santosh M.
    Puzanov, Igor
    Robert, Caroline
    Hassel, Jessica Cecile
    Sandhu, Shahneen
    Christiansen, Anita Vedel
    Lowery, Kath
    Pemberton, Kristine
    Al Hajj, Mohammad
    Diede, Scott J.
    Ehrnrooth, Eva
    Eggermont, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Phase I trial of human tyrosinase DNA vaccination in dogs with advanced malignant melanoma.
    Bergman, PJ
    McKnight, J
    Novosad, A
    Chamey, S
    Farrelly, J
    Jeffers, Y
    Egan, M
    Craft, D
    Gallardo, H
    Riviere, I
    Wulderk, M
    Hohenhaus, A
    Houghton, A
    Wolchok, J
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3754S - 3754S
  • [34] Combination of pembrolizumab (PEMBRO) plus temozolomide (TMZ) therapy in Chinese patients (pts) with advanced acral and mucosal melanoma.
    Hu, Tu
    Sun, Wei
    Xu, Yu
    Luo, Zhiguo
    Chen, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
    Adil Daud
    Japinder Gill
    Sheily Kamra
    Lei Chen
    Amit Ahuja
    Journal of Hematology & Oncology, 10
  • [36] Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
    Eroglu, Zeynep
    Chen, Ann
    Li, Jiannong
    Markowitz, Joseph
    Brohl, Andrew Scott
    Tetteh, Leticia
    Karpisek, Adam
    Taylor, Hayley
    Messina, Jane
    Sondak, Vernon K.
    Khushalani, Nikhil I.
    Smalley, Keiran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
    Silk, Ann W.
    Curti, Brendan
    Bryan, Jennifer
    Saunders, Tracie
    Shih, Weichung
    Kane, Michael P.
    Hannon, Phoebe
    Fountain, Christopher
    Felcher, Jessica
    Zloza, Andrew
    Kaufman, Howard L.
    Mehnert, Janice M.
    McDermott, David F.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] Phase I trial of sequential decitabine plus high-dose interleukin-2 (HD IL-2) in patients with advanced melanoma.
    Gollob, J
    Thoreson, M
    Richmond, T
    Sciambi, C
    Bael, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 716S - 716S
  • [39] Clinical characteristics predictive of response to pembrolizumab in advanced melanoma.
    Tsai, Katy K.
    Loo, Kimberly
    Khurana, Neharika
    Algazi, Alain Patrick
    Hwang, Jimmy
    Sanchez, Roberto
    Krummel, Matthew
    Rosenblum, Michael
    Tumeh, Paul
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.
    Carlino, Matteo S.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Fitzharris, Bernie M.
    McNeil, Catriona M.
    Hill, Andrew G.
    Ribas, Antoni
    Atkins, Michael B.
    Thompson, John A.
    Hwu, Wen-Jen
    Hodi, F. Stephen
    Menzies, Alexander M.
    Guminski, Alexander David
    Kefford, Richard
    Shu, Xinxin
    Ibrahim, Nageatte
    Moreno, Blanca Hornet
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345